Isofol initiates a stepwise process for the continued development of its drug candidate arfolitixorin
Gothenburg, Sweden, March 6, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has decided […]
Gothenburg, Sweden, March 6, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has decided […]
Gothenburg, Sweden, February 28, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the board of Isofol
Today on February 28, 2023 in Gothenburg – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), held its Extraordinary General Meeting
Today on February 13, 2023 in Gothenburg – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), held its Extraordinary General Meeting
GOTHENBURG, Sweden, February 9, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol”), will publish the company’s results for
GOTHENBURG, Sweden, January 30, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), has obtained a request to call an
GOTHENBURG, Sweden, January 20, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol”), yesterday called shareholders to an extraordinary
GOTHENBURG, Sweden, January 19, 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites the shareholders of Isofol Medical
GOTHENBURG, Sweden, January 19, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), decided today to call an extraordinary general
GOTHENBURG, Sweden, December 21, 2022 – Isofol Medical AB (publ) announced today that Chief Financial Officer (CFO) Gustaf Albèrt, who